Takhzyro Alternatives Compared
| Takhzyro (lanadelumab) | Haegarda (C1 esterase inhibitor (human)) | Orladeyo (berotralstat) |
|
|---|
| Takhzyro (lanadelumab) | Haegarda (C1 esterase inhibitor (human)) | Orladeyo (berotralstat) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Takhzyro works by binding to a protein called kallikrein and inhibiting its activity and may be used to prevent hereditary angioedema (HAE) attacks in adults, adolescents, and children aged 2 years... View more |
Prescription only
Haegarda works by replacing missing C1 protein in the blood of adults and children over the age of 6 with hereditary angioedema (HAE) preventing the generation of bradykinin and angioedema attacks... View more |
Prescription only
Orladeyo is an oral, once-daily medication that is taken to reduce angioedema attacks in adults and children over the age of 12 with HAE. It is the only oral preventive currently available (the... View more |
Related suggestions |
|||||||||||||||||||||||
| More about Takhzyro (lanadelumab) | More about Haegarda (C1 esterase inhibitor (human)) | More about Orladeyo (berotralstat) | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Takhzyro has an average rating of 9.7 out of 10 from a total of 3 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
Haegarda has an average rating of 8.0 out of 10 from a total of 2 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
Orladeyo has an average rating of 6.7 out of 10 from a total of 3 ratings on Drugs.com. 33% of reviewers reported a positive effect, while 0% reported a negative effect. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
|
View all Takhzyro side effects |
View all Haegarda side effects |
View all Orladeyo side effects |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
N/A |
N/A |
|||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Takhzyro prices |
View all Haegarda prices |
View all Orladeyo prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
|
N/A |
Other C1 esterase inhibitor (human) brands include: Berinert, Cinryze |
N/A |
||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
360 hours |
152 hours |
152 hours |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 2 drugs are known to interact with Takhzyro:
|
A total of 49 drugs are known to interact with Haegarda:
|
A total of 517 drugs are known to interact with Orladeyo:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
|
No known disease interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
August 23, 2018 |
N/A |
December 03, 2020 |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.